MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Shoaib Afzal, S. A. Jensen, B. Veiner, Ulla Vogel, J. P. Matsen, J. B. Sørensen, P. K. Andersen, H. E. Poulsen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Resumé

    Patients and methods: We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C > T and 1298A > C SNPs with real-time PCR.

    Results: The MTHFR 677C > T and 1298A > C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).

    Conclusions: The MTHFR 677C > T and 1298A > C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C > T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.

    OriginalsprogEngelsk
    TidsskriftAnnals of Oncology
    Vol/bind20
    Udgave nummer10
    Sider (fra-til)1660-1666
    ISSN0923-7534
    DOI
    StatusUdgivet - 2009

    Citer dette

    Afzal, S., Jensen, S. A., Veiner, B., Vogel, U., Matsen, J. P., Sørensen, J. B., ... Poulsen, H. E. (2009). MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Annals of Oncology, 20(10), 1660-1666. https://doi.org/10.1093/annonc/mdp046
    Afzal, Shoaib ; Jensen, S. A. ; Veiner, B. ; Vogel, Ulla ; Matsen, J. P. ; Sørensen, J. B. ; Andersen, P. K. ; Poulsen, H. E. / MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. I: Annals of Oncology. 2009 ; Bind 20, Nr. 10. s. 1660-1666.
    @article{c33d2120f54711dea1c9000ea68e967b,
    title = "MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer",
    abstract = "Patients and methods: We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C > T and 1298A > C SNPs with real-time PCR. Results: The MTHFR 677C > T and 1298A > C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).Conclusions: The MTHFR 677C > T and 1298A > C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C > T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.",
    keywords = "colorectal cancer, 5-fluorouracil, methylenetetrahydrofolate reductase, pharmacogenetics, single-nucleotide polymorphisms",
    author = "Shoaib Afzal and Jensen, {S. A.} and B. Veiner and Ulla Vogel and Matsen, {J. P.} and S{\o}rensen, {J. B.} and Andersen, {P. K.} and Poulsen, {H. E.}",
    year = "2009",
    doi = "10.1093/annonc/mdp046",
    language = "English",
    volume = "20",
    pages = "1660--1666",
    journal = "Annals of Oncology",
    issn = "0923-7534",
    publisher = "Oxford University Press",
    number = "10",

    }

    Afzal, S, Jensen, SA, Veiner, B, Vogel, U, Matsen, JP, Sørensen, JB, Andersen, PK & Poulsen, HE 2009, 'MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer', Annals of Oncology, bind 20, nr. 10, s. 1660-1666. https://doi.org/10.1093/annonc/mdp046

    MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. / Afzal, Shoaib; Jensen, S. A.; Veiner, B.; Vogel, Ulla; Matsen, J. P.; Sørensen, J. B.; Andersen, P. K.; Poulsen, H. E.

    I: Annals of Oncology, Bind 20, Nr. 10, 2009, s. 1660-1666.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    TY - JOUR

    T1 - MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

    AU - Afzal, Shoaib

    AU - Jensen, S. A.

    AU - Veiner, B.

    AU - Vogel, Ulla

    AU - Matsen, J. P.

    AU - Sørensen, J. B.

    AU - Andersen, P. K.

    AU - Poulsen, H. E.

    PY - 2009

    Y1 - 2009

    N2 - Patients and methods: We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C > T and 1298A > C SNPs with real-time PCR. Results: The MTHFR 677C > T and 1298A > C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).Conclusions: The MTHFR 677C > T and 1298A > C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C > T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.

    AB - Patients and methods: We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C > T and 1298A > C SNPs with real-time PCR. Results: The MTHFR 677C > T and 1298A > C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).Conclusions: The MTHFR 677C > T and 1298A > C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C > T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.

    KW - colorectal cancer

    KW - 5-fluorouracil

    KW - methylenetetrahydrofolate reductase

    KW - pharmacogenetics

    KW - single-nucleotide polymorphisms

    U2 - 10.1093/annonc/mdp046

    DO - 10.1093/annonc/mdp046

    M3 - Journal article

    VL - 20

    SP - 1660

    EP - 1666

    JO - Annals of Oncology

    JF - Annals of Oncology

    SN - 0923-7534

    IS - 10

    ER -

    Afzal S, Jensen SA, Veiner B, Vogel U, Matsen JP, Sørensen JB et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Annals of Oncology. 2009;20(10):1660-1666. https://doi.org/10.1093/annonc/mdp046